Expression of lncRNA-ANRIL in patients with coronary heart disease before and after treatment and its short-term prognosis predictive value.

Abstract

This study was designed to explore the expression of LncRNA-ANRIL in patients with coronary heart disease before and after treatment and its short-term survival prediction value. Eighty-three patients with coronary heart disease who came to our hospital undergoing interventional therapy were selected as a research group, 81 healthy volunteers who came to our hospital for normal physical examination during the same period were selected as a control group, and LncRNA-ANRIL of subjects in the two groups before and after treatment were detected by RT-PCR. Levels of Gensini score, lactate dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB), creatine kinase (CK), and BNP of patients in research group before treatment were evaluated and detected, and the correlation between those and LncRNA-ANRIL was analyzed. Then, the effective treatment of LncRNA-ANRIL for patients with coronary heart disease and the predictive value of poor prognosis were analyzed. The expression of LncRNA-ANRIL in patients with coronary heart disease was lower than that of normal subjects (p<0.05), and the expression levels of Gensini score, LDH, CK-MB, CK, and BNP gradually increased with the increased number of their diseased vessels (p<0.05). The expression of LncRNA-ANRIL was negatively correlated with expressions of Gensini score, LDH, CK-MB, CK, and BNP (p<0.05); ROC of LncRNA-ANRIL in predicting effective treatment, and poor prognosis of patients with coronary heart disease was over 0.9, as well as smoking; LncRNA-ANRIL, Gensini score, LDH, CK-MB, CK, and BNP were independent risk factors for the occurrence of MACE. LncRNA-ANRIL expresses low in the serum of patients with coronary heart disease, and it has high predictive value both for effective treatment and poor prognosis of them. Also, lncRNA-ANRIL is also an independent risk factor for their poor prognosis.